NASDAQ · MGNX
MacroGenics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MGNX: Nov 11, 2026
MacroGenics, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.1. The reported EPS for the same quarter last year was $0.27.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.10 | $-0.08 | $-0.12 | 2 |
| Dec 2026 | $-0.39 | $-0.23 | $-0.57 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · Fintel · The Motley Fool- Zacks · Oct 29, 4:35 PM EDTResMed (RMD) Beats Q1 Earnings and Revenue EstimatesResMed (RMD) delivered earnings and revenue surprises of +8.99% and +1.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Oct 26, 9:27 AM EDTMacroGenics Expands Lorigerlimab Trial After Interim Gynecologic Cancer Results;(RTTNews) – MacroGenics (MGNX) reported interim Phase 2 results showing that its experimental drug lorigerlimab demonstrated antitumor activity in patients with advanced clear cell gynecologic cancer (CCGC), according to data presented at the 2026 European Society for Medical Onc
- RTTNews · Oct 26, 9:27 AM EDTMacroGenics Expands Lorigerlimab Trial After Interim Gynecologic Cancer Results; Stock Down(RTTNews) – Update: Headline updated to include stock movement details.
- RTTNews · Oct 26, 9:00 AM EDTMacroGenics' Lorigerlimab Shows 25% Response Rate In Clear Cell Gynecologic Cancer(RTTNews) – MacroGenics (MGNX) reported interim Phase 2 LINNET results showing lorigerlimab achieved a 25% confirmed objective response rate and 44% disease control rate in patients with advanced clear cell gynecologic cancer.
- Fintel · Oct 23, 5:51 PM EDTMacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHNMacroGenics, Inc. today announced positive interim data from its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate (ADC), in patients with advanced solid tumors.As of the September 1, 2026 data cutoff, 85 patients had been treated across the dose-escalatio
- Zacks · Oct 9, 8:40 AM EDTIs MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?Here is how MacroGenics (MGNX) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
- Zacks · Sep 23, 9:40 AM EDTAre Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?Here is how C4 Therapeutics, Inc. (CCCC) and MacroGenics (MGNX) have performed compared to their sector so far this year.
- Fintel · Sep 14, 3:45 AM EDTMacroGenics Consensus Price Target Rises 12% to $9.52The average one-year price target for MacroGenics (NASDAQGS:MGNX) has been revised to $9.52 / share. This is an increase of 12.00% from the prior estimate of $8.50 dated August 25, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute a
- The Motley Fool · Aug 18, 5:58 AM EDTGilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.Gilead has been quite active in acquisitions this year.
- Zacks · Aug 13, 6:50 PM EDTMacroGenics (MGNX) Reports Q2 Loss, Lags Revenue EstimatesMacroGenics (MGNX) delivered earnings and revenue surprises of +32.50% and -25.45%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 11, 7:10 PM EDTSanara MedTech Inc. (SMTI) Tops Q2 Earnings EstimatesSanara MedTech (SMTI) delivered earnings and revenue surprises of +150.00% and -4.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 5:40 PM EDTMaravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue EstimatesMaravai LifeSciences (MRVI) delivered earnings and revenue surprises of +60.00% and +4.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for MacroGenics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.